MRK’s KEYTRUDA® FDA Approval: A Game Changer!

Overview: Merck & Co. (NYSE: MRK) has secured a pivotal FDA approval for its blockbuster immunotherapy Keytruda (pembrolizumab), marking a significant expansion of its oncology franchise. The latest approval – Keytruda (and the new subcutaneous formulation Keytruda QLEX) in combination with Padcev for certain bladder cancer patients – allows Merck to treat earlier-stage disease in patients ineligible for standard chemo (www.marketscreener.com). This is a potential game-changer that not only broadens Keytruda’s reach but also fortifies Merck’s near-term growth as it approaches a major patent cliff in 2028 (www.trefis.com). Keytruda has been the main engine of Merck’s growth, with 2024 sales hitting a record ~$29.5 billion – surpassing even Humira’s peak sales (elpais.com) – and 2025 sales reaching $31.7 billion (www.marketscreener.com). Below, we dive into Merck’s dividend profile, leverage, valuation, and the risks and questions facing the company as it navigates this Keytruda-powered era.

Don't wait — first dividend checks could arrive any day.

Get the concise guide to start collecting royalty checks now.

Get Instant Access
✕

Dividend Policy & History

Merck has a long-standing commitment to dividends, backed by a 55-year streak of uninterrupted payouts (za.investing.com). The company currently offers a dividend yield around ~3%, reflecting recent increases. In late 2025, Merck’s board raised the quarterly dividend to $0.85 per share, up ~5% year-over-year (za.investing.com). This brought the annualized payout to $3.40, yielding about 2.8–3.5% (depending on share price) in early 2026 (www.macrotrends.net) (za.investing.com). Key points on the dividend include:

– Consistent Growth: Merck grows its dividend at a moderate pace (5% in the last year) (za.investing.com), balancing shareholder returns with reinvestment needs. The dividend per share has risen steadily from ~$2.60 in 2018 to $3.40 recently. – Payout Ratio: The payout is reasonable but elevated for Big Pharma. In 2025, dividends consumed roughly 60% of GAAP earnings and ~65% of free cash flow (FCF) (www.trefis.com). Merck generated about $17 billion in operating cash flow and ~$13 billion FCF over the last 12 months (www.trefis.com), comfortably covering the ~$8.6 billion in annual dividends. – Dividend Safety: Given Merck’s stable cash flows from its pharmaceuticals and vaccines portfolio, the dividend appears secure in the near term. Interest expense remains modest (~$1 billion in 2022) relative to operating profit (www.sec.gov), and cash flow coverage of both debt obligations and dividends is solid. However, Merck’s payout ratio is higher than some peers, limiting flexibility if earnings were to stagnate. Management’s willingness to keep raising the dividend signals confidence in future cash generation, but investors should monitor upcoming patent expirations (e.g. Keytruda) for potential impact on dividend sustainability.

Leverage, Debt Maturities & Balance Sheet

Merck’s balance sheet reflects the company’s growth investments and acquisitions in recent years. Debt levels have risen as Merck acquired new assets to prepare for the post-Keytruda era. Key highlights:

– Debt Load: As of late 2025, Merck carried roughly $77 billion in long-term debt (up from ~$28.7 billion at the end of 2022) (www.sec.gov) (www.macrotrends.net). This increase stems largely from recent acquisitions – e.g. the $10 billion Verona Pharma deal for an inhaled COPD drug in 2025 (apnews.com) and the $10.8 billion Prometheus Biosciences immunology acquisition in 2023. Merck’s debt-to-equity ratio has climbed to about 1.5× (150%) by 2025, from ~0.8× a few years prior (www.macrotrends.net). Despite the higher leverage, Merck retains a strong credit profile (rated A/Aa by agencies), reflecting its robust cash flows and substantial equity base (~$50 billion+). – Maturity Profile: Merck’s debt is long-dated and laddered, reducing near-term refinancing risk. Only a small portion of debt comes due in the next 1–2 years (e.g. legacy notes like a $750 million bond matured in 2024 and a ~$135 million debenture due 2026) (www.sec.gov). The majority of Merck’s borrowings mature from 2027 onward, with sizable tranches in 2027–2031 and beyond (www.sec.gov) (www.sec.gov). Recent debt raises have locked in fixed rates (3.8–5.7% coupons) on 7, 10, and even 30-year notes (www.sec.gov). This staggered maturity schedule and Merck’s ~$13 billion cash on hand (est. year-end 2025) provide confidence that the company can meet obligations without straining liquidity. – Interest Coverage: Merck’s earnings easily cover its interest expense. In 2022, interest expense was under $1 billion (www.sec.gov), while EBITDA was on the order of $20+ billion. Even as debt has increased, interest costs remain manageable (some older debt carried low coupons ~2–3%). Interest coverage by EBITDA is well into the high single digits, indicating low default risk. Merck also has flexibility with a commercial paper program and high-grade market access if additional financing is needed (www.sec.gov). – Financial Policy: Management has emphasized maintaining a strong investment-grade credit. Merck’s total debt-to-capital ratio was ~28% at end of 2022, down from 35% in 2020, before the recent M&A wave (www.sec.gov). While leverage has ticked up post-2022, the company signaled it views current debt levels as acceptable given growth prospects. Cash generation is prioritized for organic R&D, dividends, and strategic deals, rather than aggressive stock buybacks. In fact, Merck temporarily paused share repurchases around its Organon spin-off and major acquisitions, instead using cash and debt to fund deals (www.sec.gov). This prudent capital allocation has kept leverage within manageable bounds and preserves capacity for future opportunities.

Valuation & Comparables

Merck’s valuation reflects a balance between its strong current franchise and future uncertainties. The stock trades at a modest earnings multiple relative to peers, suggesting that investors are cautious about Merck’s post-2028 outlook (when Keytruda’s U.S. exclusivity lapses). Key valuation metrics:

– Earnings Multiple: Merck’s forward price-to-earnings (P/E) ratio is in the mid-teens. Based on 2025 guidance (adjusted EPS ~$8.90) (apnews.com) and a stock price in the $105–115 range, Merck’s forward P/E hovered around 12×–13× during early 2025. Even after a recent rally to ~$117/share (www.marketscreener.com), the stock’s trailing P/E is still roughly in the high-teens. This is a discount to the pharma industry average and especially to high-growth peers. For instance, Eli Lilly’s multiple (>40×) is much higher due to its booming diabetes/obesity franchise, while Pfizer trades around ~8–10× after its COVID-19 vaccine windfall faded (www.macrotrends.net). Merck’s valuation sits in between, closer to value-oriented names like AbbVie or J&J (low-20s P/E) (www.macrotrends.net), but well below growth-heavy biotech valuations. The subdued multiple signals that the market is pricing in Merck’s mid-term patent risk and lower growth profile beyond Keytruda. – Relative Value: By other measures, Merck appears reasonably valued. Its EV/EBITDA is similarly in the low-teens, and the stock offers an earnings yield (E/P) of ~8% plus a 3% dividend yield – roughly a ~11% “total yield” to shareholders (www.trefis.com) (www.trefis.com). According to Trefis data, Merck’s earnings yield and dividend yield combined equate to about a 10% total yield, meaning the stock provides a ~5.8% equity risk premium over 10-year Treasuries (www.trefis.com). This suggests the stock is attractively valued relative to the market, assuming Merck can sustain earnings. However, the overhang of Keytruda’s patent expiry tempers enthusiasm – investors are not (yet) willing to award Merck a premium multiple despite its current growth, resulting in a share price that appears cheap against today’s earnings. – Growth Expectations: Sell-side forecasts imply low single-digit revenue growth for Merck over the next few years (≈3–4% annually (simplywall.st)), as newer products ramp up but major franchises face headwinds. In early 2025, Merck projected full-year revenue of $64–65.6 billion (apnews.com) (roughly flat vs. 2024, due in part to a China vaccine sales pause). Adjusted EPS guidance of ~$9 was slightly below consensus (apnews.com), reinforcing perceptions of limited near-term upside. This cautious outlook contributes to Merck’s depressed multiple. If Merck can outperform these expectations – for example, if Keytruda’s new indications drive bigger gains, or if pipeline assets surprise to the upside – there is room for multiple expansion. Conversely, any signs of growth faltering or pipeline disappointments could pressure the stock further. In sum, Merck’s valuation is cheap on paper but justifiably so given looming risks; it will likely remain in a value range until there’s clarity on its post-Keytruda earnings trajectory.

Risks & Red Flags

Despite Merck’s strong execution and Keytruda’s success, investors face several key risks and red flags:

– Keytruda Concentration & Patent Cliff (2028): Merck’s biggest risk is its overreliance on Keytruda, which accounts for ~45–50% of total sales (www.marketscreener.com) (www.marketscreener.com). The primary U.S. patent for Keytruda expires in 2028 (www.sec.gov), after which biosimilar competition could rapidly erode sales. This is a looming “cliff” – Keytruda’s impending 2028 expiration is explicitly cited as Merck’s top risk by analysts (www.trefis.com). The company is racing to extend Keytruda’s franchise (e.g. new combo therapies and a subcutaneous form, Keytruda QLEX) and to build up other revenue streams before the cliff hits. Nevertheless, the sheer size of Keytruda (~$30B/year) means replacing this revenue will be challenging. Any hiccup (such as faster-than-expected biosimilar entry or narrower new indications) would be a major blow to Merck’s future earnings. – Pipeline and Acquisition Execution: To mitigate the patent cliff, Merck has been on an M&A spree, acquiring companies like Prometheus, Verona Pharma, and (as rumored) Cidara. While these deals bring promising candidates (for autoimmune diseases, respiratory conditions, etc.), they carry integration and development risk. If these pipeline assets fail in trials or launch into crowded markets, Merck could be left with high goodwill and debt but little revenue payoff. The company’s recent acquisitions totaled over $25 billion; a red flag is that goodwill and intangibles on the balance sheet have swelled (signaling reliance on bought innovation). Merck must prove it can turn these deals into real growth. A related risk is overpaying for acquisitions – the biotech market is competitive, and Merck paid large premiums (e.g. ~$10.8B for Prometheus’s Phase 2 IL-23 drug (www.axios.com)). If the science doesn’t pan out, write-downs or impairments could follow. – Regulatory & Pricing Pressure: The pharmaceutical industry faces intensifying pressure on drug pricing and regulation. In the U.S., the Inflation Reduction Act (IRA) will empower Medicare to negotiate prices on top drugs later this decade, potentially including Keytruda if it remains a big seller beyond 2028. Merck has even sued the U.S. government, arguing the IRA’s pricing provisions are unconstitutional “extortion,” underscoring how seriously it views this threat (www.sec.gov) (www.sec.gov). Additionally, political rhetoric on drug pricing (calls for “most-favored-nation” pricing, etc.) creates an overhang (moneyweek.com) (moneyweek.com). Globally, reference pricing and healthcare budget pressures could limit Merck’s ability to grow by raising prices. Regulatory risks also include potential safety issues or rulings: as Merck rapidly expands Keytruda into new populations (like early-stage cancers), rare adverse events could emerge. Any major safety scare or withdrawal (akin to Merck’s Vioxx episode in 2004) would be a serious red flag, though nothing of that magnitude is currently evident. – Market Dynamics (China and Emerging Markets): Merck enjoys growth in emerging markets, but this can be volatile. For example, Gardasil (HPV vaccine) sales plunged ~34% in 2025 due to a demand slowdown in China (www.marketscreener.com) (apnews.com). In fact, Merck halted Gardasil shipments to China for part of 2025 to clear excess inventory (apnews.com) (apnews.com). Such issues highlight geopolitical and economic risks: a soft Chinese economy or policy change can sharply impact Merck’s vaccine and pharma sales. Merck’s other internationally exposed franchises (diabetes drugs, etc.) face similar uncertainties with foreign exchange swings (apnews.com), local competition, or slower uptake. These factors are largely outside Merck’s control yet can hit earnings, representing a risk for investors counting on steady growth. – Operational & Other Risks: Merck’s Animal Health division (a steady mid-single digit growth business) could be affected by agricultural cycles or disease outbreaks in livestock. Also, any delays or cost overruns in manufacturing new products (e.g. the launch of complex biologics like Keytruda QLEX) could squeeze margins. On the financial side, higher interest rates are a minor risk – while most of Merck’s debt is fixed-rate, new borrowing costs have risen (recent 30-year bonds were issued at ~5.7% (www.sec.gov), up from sub-3% levels before). If Merck needed to refinance a large amount or raise significant new debt, interest expense would increase. Finally, legal contingencies bear watching: Merck is involved in various patent disputes and product liability cases (common for pharma). No single case appears threatening now, but unexpected legal losses or a large settlement could create a one-time financial hit.

Open Questions & Future Outlook

Merck’s recent FDA win for Keytruda underscores its strength today, but big questions remain about tomorrow. Investors and analysts are focused on several open questions as the Merck story unfolds:

– How will Merck fill the Keytruda void post-2028? With Keytruda’s U.S. patent expiry in sight, Merck’s strategy is to extend and expand the franchise (new combinations like Keytruda+Padcev (www.marketscreener.com), new formulations like QLEX, and potential next-gen immunotherapies) while building up other pillars. The open question is: Can these efforts collectively replace tens of billions in lost Keytruda sales? Success in emerging areas – such as Merck’s collaboration with Moderna on personalized mRNA cancer vaccines (which showed encouraging 5-year data in melanoma (www.marketscreener.com)) – could be game-changing, but these are still early-stage. The outcome will determine Merck’s growth trajectory in the 2030s. – Will recent acquisitions pay off? Merck has spent heavily on M&A to bolster its pipeline (from immunology with Prometheus to respiratory with Verona’s COPD drug, to potential deals in antifungals like Cidara (cincodias.elpais.com)). An open question is whether these assets will achieve their forecasted potential. For instance, Winrevair (sotatercept) for pulmonary hypertension – acquired via Acceleron – launched to $1.4B in its first year (www.marketscreener.com). Can it continue to grow into a multi-billion franchise? Similarly, can the inhaled COPD drug Ohtuvayre (from Verona) significantly boost Merck’s revenues? Investors will be watching clinical results and launch traction for these pipeline products closely. Any shortfall could leave a gap in Merck’s future earnings plan. – How will Merck navigate the drug pricing and policy landscape? As noted, Merck is fighting the Medicare price negotiation policy and adapting to new regulations. An open question is how successful these efforts will be. Could Merck’s legal challenges alter the implementation of drug price negotiation, or will the company find ways to pivot (e.g. focusing on drugs in protected therapeutic areas, or shifting more sales to private markets)? Additionally, how will global policy changes (such as potential U.S. tariffs on imported drugs (apnews.com) or European pricing reforms) affect Merck’s operations? The outcome of these policy battles will shape industry profitability and could either alleviate a major headwind or introduce new hurdles for Merck. – What is the next “big thing” for Merck? Beyond extending Keytruda, investors are looking for the next major growth driver. Merck has several possibilities on the horizon – e.g. Gefapixent for chronic cough, Lynparza and Lenvima (oncology drugs via partnerships), or entirely new classes like oral PCSK9 inhibitors for cholesterol (Merck’s candidate enlicitide showed promising Phase 3 results (za.investing.com)). There’s also the question of business development: will Merck pursue another large acquisition (as it contemplated with Seagen in 2022 (apnews.com)) to instantly scale up oncology or other segments? Or will it focus on smaller bolt-ons? The strategic direction Merck takes – doubling down on oncology versus diversifying – remains an open question that will influence its risk profile and valuation. – Can Merck maintain margin strength amid these changes? Merck currently enjoys healthy operating margins (~35% in 2025) (www.trefis.com). But as the product mix shifts (more revenue from lower-margin areas like vaccines or new launches with high marketing spend) and with possible pricing pressures, maintaining margins is not guaranteed. Investors will be asking: Can Merck execute on cost control and efficiency (especially in manufacturing and SG&A) to protect margins even if pricing erodes? The company’s ability to optimize its cost base, while still investing heavily in R&D (~$13B annually (www.sec.gov)), will be a key determinant of its long-term earnings power.

Conclusion: Merck’s FDA approval for Keytruda in a new indication highlights the company’s innovative prowess and boosts its growth runway in the near term. Keytruda truly has been a game changer – transforming Merck into an oncology powerhouse and delivering record-breaking sales (elpais.com). The challenge for Merck and its investors is ensuring that this game-changing success today does not become a vulnerability tomorrow. The company’s dividend is solid, its balance sheet is strong enough to support ongoing R&D and deal-making, and its valuation is relatively low – all positives for the stock. However, the clock is ticking on Keytruda’s dominance. How Merck manages the risks and opportunities ahead – from pipeline execution to patent expirations and policy shifts – will determine if this pharma giant can continue to outperform or if it will face a difficult reset in the post-Keytruda era. For now, Merck’s latest Keytruda win cements its leadership in immuno-oncology (www.marketscreener.com) and gives management valuable time to orchestrate the next act for MRK shareholders.

Sources: The analysis above is grounded in Merck’s official financial disclosures, investor communications, and credible financial media. Key figures on Merck’s debt, cash flow, and dividend come from the company’s SEC filings and earnings releases (www.sec.gov) (za.investing.com). Information on the FDA approvals and product performance (Keytruda, Winrevair, Gardasil, etc.) is drawn from Merck’s 2025 results announcement and press materials (www.marketscreener.com) (www.marketscreener.com). Valuation and peer comparisons utilize market data as of early 2026 (www.macrotrends.net) (apnews.com). All statements are supported by the cited sources.

For informational purposes only; not investment advice.